Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension Study of Inhaled GB002 in Pulmonary Arterial Hypertension
NCT04816604Phase 2Terminated
- Sponsor
- Gossamer Bio
- Start
- Apr 2021
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of seralutinib in pulmonary arterial hypertension (PAH), sponsored by Gossamer Bio. Started Apr 2021; status: terminated.
02
Drugs
seralutinib
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04816604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04816604.